{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:27:52Z","timestamp":1774438072878,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.clinthera.2013.12.001","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T20:31:28Z","timestamp":1388781088000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the Pharmacokinetics, Safety, and Tolerability of Vitamin D3 in DP-R206 (150-mg Ibandronate\/24,000-IU Vitamin D3 Tablet) and as Monotherapy (24,000 IU) in Healthy Male Korean Adults"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01577849","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ji-Young","family":"Jeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jin","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Wan","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Gul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2013.12.001_bib1","first-page":"S164","article-title":"Osteoporosis and the burden of osteoporosis-related fractures","volume":"17","author":"Dempster","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.12.001_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2147\/TCRM.S3552","article-title":"The use of calcium and vitamin D in the management of osteoporosis","volume":"4","author":"Sunyecz","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2013.12.001_bib4","series-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","year":"2013"},{"key":"10.1016\/j.clinthera.2013.12.001_bib5","series-title":"Dietary Reference Intakes for Calcium and Vitamin D","year":"2011"},{"key":"10.1016\/j.clinthera.2013.12.001_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2265.1999.00764.x","article-title":"Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis","volume":"51","author":"Sahota","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clinthera.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SMJ.0b013e31819ed0dd","article-title":"Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates","volume":"102","author":"Binkley","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.clinthera.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.clinthera.2009.07.018","article-title":"Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review","volume":"31","author":"Rossini","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.12.001_bib10","first-page":"3","article-title":"Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis","volume":"2","author":"Bauss","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2013.12.001_bib11","first-page":"174","article-title":"Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs","volume":"7","author":"Schacht","year":"2007","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.clinthera.2013.12.001_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","article-title":"Safety considerations with bisphosphonates for the treatment of osteoporosis","volume":"30","author":"Strampel","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2013.12.001_bib13","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use(CHMP). Guideline on the Investigation of Bioequivalence; London, 20 January 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf. Accessed July 12, 2013"},{"key":"10.1016\/j.clinthera.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2165\/0003495-200868180-00011","article-title":"Ibandronate: a review of its use in the management of postmenopausal osteoporosis","volume":"68","author":"Frampton","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2013.12.001_bib16","unstructured":"Highlights of prescribing information Boniva\u00ae (ibandronate sodium) tablets. In: Genentech USA, Inc, A Member of the Roche Group, South San Francisco, CA. Revised: April 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021455s014s015lbl.pdf. Accessed July 12, 2013."},{"key":"10.1016\/j.clinthera.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clinthera.2006.04.006","article-title":"Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen","volume":"28","author":"Pyon","year":"2006","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:17Z","timestamp":1758962957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813011090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0149291813011090"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.12.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Pharmacokinetics, Safety, and Tolerability of Vitamin D3 in DP-R206 (150-mg Ibandronate\/24,000-IU Vitamin D3 Tablet) and as Monotherapy (24,000 IU) in Healthy Male Korean Adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}